Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Atomic Force Microscopy Based Single Molecule Recognition: Deciphering Biological Interactions at the Nanoscale.

Journal of molecular recognition : JMR·2026

Same author

Low-Valent Rhodium and Iridium Assemblies Directed by Uracilate and Guaninate Linkers.

Inorganic chemistry·2026

Same author

How did climate drive the historical distribution of relict plants: a case study on <i>Metasequoia</i> using deep-time ecological niche modelling.

PeerJ·2026

Same author

Electrostatic force microscopy in biomedicine: From molecular charge transport to cellular electrophenotyping.

Biophysical chemistry·2026

Same author

Kangfuxin solution perianal warm moist compress combined with music therapy for anal fullness after endoscopic treatment of internal hemorrhoids.

Frontiers in medicine·2026

Same author

Ultraslow conformational dynamics and catch bond formation of a bacterial adhesin revealed by a single-domain variant of FimH.

Proceedings of the National Academy of Sciences of the United States of America·2026

Search research articles

Related Experiment Video

Updated: May 14, 2026

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Published on: August 14, 2017

Targeting von Willebrand factor selectively under inflammatory conditions.

Gianluca Interlandi¹, Victoria S Carter¹, Yi Wang²

¹Department of Bioengineering, University of Washington, Seattle, WA 98195, USA.

Biorxiv : the Preprint Server for Biology

|May 13, 2026

Summary

Developing novel anti-thrombotic drugs is crucial. This study identifies lumacaftor as a potential therapeutic that selectively inhibits von Willebrand factor (VWF) under oxidizing inflammatory conditions, reducing bleeding risks.

Keywords:

Haemostasis and thrombosis anti-thrombotic molecules drug screening enzyme-linked immunosorbent assay inflammation ligand docking methionine oxidation

More Related Videos

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

Related Experiment Videos

Last Updated: May 14, 2026

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Published on: August 14, 2017

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

Area of Science:

Biochemistry
Pharmacology
Hematology

Background:

Developing targeted anti-thrombotic therapies that avoid bleeding complications remains a significant challenge.
Current anticoagulants lack specificity, affecting normal clotting processes.
Inflammation-induced oxidation activates von Willebrand factor (VWF), presenting a therapeutic target.

Purpose of the Study:

To investigate lumacaftor's potential as a selective inhibitor of VWF under oxidizing conditions.
To develop and validate a high-throughput assay for screening VWF inhibitors.

Main Methods:

Computational screening identified lumacaftor for its potential selective VWF inhibition.
An enzyme-linked immunosorbent assay (ELISA) was developed to assess VWF binding to platelet glycoprotein Ib α.
VWF activity was compared under both oxidizing and non-oxidizing conditions.

Main Results:

The developed ELISA demonstrated lumacaftor's ability to inhibit VWF binding selectively under oxidizing conditions.
Results support lumacaftor's potential as an anti-thrombotic agent active only during inflammation.
The assay proves effective for high-throughput screening of VWF inhibitors.

Conclusions:

Lumacaftor exhibits promising selective anti-VWF activity in the presence of oxidation, mimicking inflammatory states.
The developed assay offers a robust platform for discovering new anti-thrombotic drugs with improved safety profiles.